Member Info for liquid1

finnCap bullish

Mark Brewer, analyst at broker finnCap, increased his price target to 360p, which implies 886% ‘upside’ from Friday’s close of 36.5p.

He added that quantifying the coronavirus opportunity was “nigh on impossible” as he admitted the valuation “could go substantially higher”.

What happens next will depend on the “upcoming discussions with regulators, which should clarify the route to market and the potential for buying SNG001 ahead of the winter 2020 flu season and the possibility of a second wave of COVID-19”.

https://www.proactiveinvestors.com/companies/news/924546/synairgen-rockets-as-trial-results-could-signal--major-breakthrough--in-treatment-of-severely-ill-covid-19-patients-924546.html

https://www.worldometers.info/coronavirus/

This could help save them

Was on LBC also at 1:00pm news

Treatment for recovered patients who are having difficulty breathing!

Nice

finnCap bullish
Mark Brewer, analyst at broker finnCap, increased his price target to 360p, which implies 886% ‘upside’ from Friday’s close of 36.5p.

He added that quantifying the coronavirus opportunity was “nigh on impossible” as he admitted the valuation “could go substantially higher”.

What happens next will depend on the “upcoming discussions with regulators, which should clarify the route to market and the potential for buying SNG001 ahead of the winter 2020 flu season and the possibility of a second wave of COVID-19”.

https://www.proactiveinvestors.com/companies/news/924546/synairgen-rockets-as-trial-results-could-signal--major-breakthrough--in-treatment-of-severely-ill-covid-19-patients-924546.html

https://*********************/companies/uk/pharmaceuticals/synairgen/research/finncap/synairgen-covid-19-treatment-positive-phase-ii-data/8_21387

Degsey

Do you have a link to that target?

Coronavirus drug from Synairgen hailed a game changer after trial found it cut need for intensive care
The treatment uses a protein called interferon beta which the body produces when it gets a viral infection

By
Jamie Johnson
20 July 2020 • 10:12am
Vials
Synairgen, a Southampton based company, has developed SNG001 - a drug which has been found to prevent Covid-19 coronavirus becoming more severe in around 79% of cases, it says CREDIT: Akio Kon/Bloomberg
A coronavirus treatment drug has been hailed as a potential “game changer” after preliminary results of a clinical trial suggest it could dramatically reduce the number of patients needing intensive care....

https://www.telegraph.co.uk/news/2020/07/20/coronavirus-treatment-synairgen-hailed-game-changer-trial-results/

Fund117 Jul '20 - 15:21 - 2972 of 2982
0 0 0
This is an email I received. Let’s not forget an offer of 20p that was considered poor was not long ago and they obviously went through the books and everything before making the offer. Here’s the email reply I received.
--------------------------------------------------------------------------------------------
Thank you for your email. It is very difficult for us to comment on the
share price. I can assure you we are working very hard to address the
challenges that we face. As we are in a close period ahead of our results
announcement, I am very limited in what I can discuss with you now.

0.397p to buy

Ask is 0.388

Intraday RNS or Monday 7:00am

https://www.google.co.uk/amp/s/amp.theguardian.com/business/2020/jul/16/boohoo-shares-rise-12-after-co-founders-pump-15m-into-company

Home » Reports » Boohoo Group PLC 49.6% Potential Upside Indicated by Bernstein

Boohoo Group PLC 49.6% Potential Upside Indicated by Bernstein
Article by: Amilia Stone 14th July 2020

Boohoo Group PLC with EPIC/TICKER (LON:BOO) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘OUTPERFORM’ today by analysts at Bernstein. Boohoo Group PLC are listed in the Consumer Services sector within AIM. Bernstein have set their target price at 350 GBX on its stock. This is indicating the analyst believes there is a potential upside of 49.6% from the opening price of 234 GBX. Over the last 30 and 90 trading days the company share price has decreased 137.7 points and decreased 33 points respectively. The 1 year high share price is 433.5 GBX while the year low stock price is currently 133.1 GBX.

www.***************************/boohoo-group-plc-49-6-potential-upside-indicated-by-bernstein/412842074

Company:


Director Position Number of Average Number of Percentage
Ordinary purchase Ordinary of issued
Shares purchased price Shares held share
or interest capital
in Ordinary
Shares following
the purchase
Executive 214.281
Mahmud Kamani Chairman 5,000,000 pence 157,679,880 12.5%
------------------ ------------------ ------------- ------------------ -----------
Group Co-Founder
and Executive 214.281
Carol Kane Director 2,000,000 pence 33,330,421 2.6%
------------------ ------------------ ------------- ------------------ -----------
Non-Executive
Iain McDonald Director 50,000* 226.5 pence* 518,481 0.04%
-----------------

"With the commercial terms settled in the agreement in principal, the legal language over a number of agreements has taken time to conclude."

https://www.investegate.co.uk/canadian-o--39-seas-petr--copl-/rns/shorecan-and-essar-mauritius-extend-backstop-date/202007100700036039S/

Exploration Upside
• Nduri Far East Prospect – Growth Fault-related rollover anticline
• Noa Northern “Big Kahuna” Prospect – including HJ South and Noa Northern
At the request of COPL, Netherland Sewell Associates Inc. (NSAI) has prepared an independent report in
accordance with Canadian National Instrument 51-101 evaluating the Contingent and Prospective Resources
attributed to OPL 226, as at 1 March, 2016. NSAI did not use ShoreCan seismic inversion products in their
analysis and estimates of independent reserves/resources evaluation. In this report, the Gross Unrisked
Prospective Oil Resources (recoverable) for these three prospective exploration areas are estimated to be:
Prospects Low Estimate Best Estimate High Estimate
Nduri Far East 10.9 million BO 19.9 million BO 34.9 million BO
Noa Northern 24.6 million BO 43.9 million BO 76.6 million BO
HJ South 36.8 million BO 61.3 million BO 98.9 million BO
Totals 72.3 million BO 125.1 million BO 210.4 million BO

http://www.canoverseas.com/wp-content/uploads/2017/06/OPL226-Project-Summary-May-2017-Final.pdf

Game changing RNS imminent

RNS today, tomorrow or Monday

And Canadian Overseas Petroleum Limited (LON:COPL) announced its 50%-owned joint venture ShoreCan had agreed an extension to the backstop date to sign-off definitive documents to seal the resolution of its dispute with Essar, Shorecan’s partner in Nigeria. The new date has been set as July 20, the company said.

"The time taken to enter into the definitive documents has taken longer than both parties thought at the outset,” said Arthur Millholland, COPL chief executive, said in a statement. “With the commercial terms settled in the agreement in principle, the legal language over a number of agreements has taken time to conclude. We are close to completion on these, but with both parties working amicably we just ran out of time.

“We continue to look forward to the future working relationship with Essar to unlock the potential of OPL 226."

Nigeria (OPL 226)
---OPL 226 is located in the shallow offshore region of the prolific Niger Delta with water depths of 40 to 180 meters.
---Offshore OPL-226 was awarded to Essar in March 2010. Essar has 100% PI and is the Operator in this block.
---Essar completed 568 Km2 of 3D API seismic and has plans to complete the 1 Exploratory well as committed in the MWP.
---GCA has certified 12 MMBbl oil and 163 BCF gas in the block

http://115.124.126.156/wordpress/eogpl/nigeria-2/